Skip to content
Info Ciudad -24

Info Ciudad -24

Business Soothes The Nerves

Primary Menu Info Ciudad -24

Info Ciudad -24

  • Business Investment
  • Insurance Florida
  • P&C Insurance
  • Business News
  • Bbc Business
  • About Us
    • Advertise Here
    • Contact Us
    • Privacy Policy
    • Sitemap
  • Business Investment

Allspring Global Investments Holdings LLC Makes New Investment in Incyte Co. (NASDAQ:INCY)

1 month ago Ethel

Incyte logoAllspring Global Investments Holdings LLC acquired a new position in Incyte Co. (NASDAQ:INCY – Get Rating) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 109,461 shares of the biopharmaceutical company’s stock, valued at approximately $8,034,000.

Several other large investors have also modified their holdings of the business. IndexIQ Advisors LLC boosted its stake in shares of Incyte by 5.1% during the 3rd quarter. IndexIQ Advisors LLC now owns 3,222 shares of the biopharmaceutical company’s stock worth $222,000 after purchasing an additional 157 shares during the period. Bank Julius Baer & Co. Ltd Zurich boosted its position in Incyte by 6.0% in the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 2,823 shares of the biopharmaceutical company’s stock valued at $194,000 after buying an additional 160 shares during the period. National Asset Management Inc. boosted its position in Incyte by 5.3% in the 4th quarter. National Asset Management Inc. now owns 3,255 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 164 shares during the period. Ieq Capital LLC boosted its position in Incyte by 5.1% in the 3rd quarter. Ieq Capital LLC now owns 3,394 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 165 shares during the period. Finally, State of Michigan Retirement System raised its holdings in shares of Incyte by 0.4% in the 4th quarter. State of Michigan Retirement System now owns 47,304 shares of the biopharmaceutical company’s stock valued at $3,472,000 after purchasing an additional 200 shares in the last quarter. 91.33% of the stock is owned by institutional investors and hedge funds.

NASDAQ:INCY opened at $83.18 on Monday. Incyte Co. has a 12 month low of $61.91 and a 12 month high of $88.26. The stock has a 50 day moving average of $73.33 and a two-hundred day moving average of $70.54. The company has a current ratio of 3.65, a quick ratio of 3.62 and a debt-to-equity ratio of 0.01. The firm has a market cap of $18.41 billion, a P/E ratio of 19.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.73.

Incyte (NASDAQ:INCY – Get Rating) last released its quarterly earnings data on Tuesday, February 8th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.72). Incyte had a net margin of 31.76% and a return on equity of 14.66%. The business had revenue of $862.50 million during the quarter, compared to analyst estimates of $813.38 million. During the same quarter in the prior year, the company posted $0.73 earnings per share. The company’s revenue was up 9.4% on a year-over-year basis. On average, research analysts forecast that Incyte Co. will post 2.52 earnings per share for the current year.

Related Posts:

  • Nordea Investment Management AB Reduces Holdings in Highwoods Properties, Inc. (NYSE:HIW)

Several research firms have recently commented on INCY. Guggenheim reduced their price target on shares of Incyte from $118.00 to $104.00 in a report on Monday, January 3rd. SVB Leerink lowered shares of Incyte from a “market perform” rating to an “underperform” rating and reduced their price target for the company from $60.00 to $56.00 in a report on Wednesday, February 9th. Royal Bank of Canada upgraded shares of Incyte from a “sector perform” rating to an “outperform” rating and boosted their price target for the company from $78.00 to $90.00 in a report on Tuesday, January 18th. Morgan Stanley reduced their price target on shares of Incyte from $77.00 to $76.00 and set an “equal weight” rating for the company in a report on Wednesday, February 2nd. Finally, JMP Securities reiterated a “buy” rating and set a $108.00 price objective on shares of Incyte in a research note on Friday, December 17th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $87.82.

In other news, Director Bros. Advisors Lp Baker bought 99,800 shares of the stock in a transaction on Tuesday, February 22nd. The stock was purchased at an average cost of $68.07 per share, with a total value of $6,793,386.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Jonathan Elliott Dickinson sold 7,375 shares of the business’s stock in a transaction on Monday, January 31st. The shares were sold at an average price of $74.19, for a total transaction of $547,151.25. The disclosure for this sale can be found here. Over the last quarter, insiders bought 711,335 shares of company stock worth $49,689,821. Insiders own 15.80% of the company’s stock.

Incyte Company Profile (Get Rating)

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib).

Featured Articles

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY – Get Rating).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Want More Great Investing Ideas?

Receive News & Ratings for Incyte Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Incyte and related companies with MarketBeat.com’s FREE daily email newsletter.

Tags: Amazon Business Login, Amazon Business Prime, Bank Of America Business Account, Best Business Schools, Business Attorney Near Me, Business Bank Account, Business Card Holder, Business Card Maker, Business Card Template, Business Cards Near Me, Business Casual Attire, Business Casual Shoes, Business Casual Woman, Business Plan Examples, Ca Business Search, Ca Sos Business Search, Capital One Business Credit Card, Chase Business Checking, Chase Business Credit Cards, Chase Business Customer Service, Chase Business Login, Chase Business Phone Number, Cheap Business Cards, Citizens Business Bank, Cox Business Login, Digital Business Card, Facebook Business Suite, Finance In Business, Free Business Cards, Google Business Login, Harvard Business School, Lands End Business, Massage Parlor Business Near Me, Michigan Business Entity Search, Mind Your Business, Mind Your Own Business, Ohio Business Search, Risky Business Costume, Skype For Business, Small Business Loan, Small Business Saturday 2021, Starting A Business, Texas Business Entity Search, Triumph Business Capital, Vending Machine Business, Verizon Business Customer Service, Vonage Business Login, Wells Fargo Business Account, Yahoo Small Business, Yahoo Small Business Login

Continue Reading

Previous Federal Realty Investment Trust (NYSE:FRT) Given New $125.00 Price Target at Wells Fargo & Company
Next Before giving billions to Jared Kushner, Saudi investment fund had big doubts

More Stories

  • Business Investment

My Investment Portfolio Is Down 25%. Here’s Why I’m Not Worried | Smart Change: Personal Finance

3 hours ago Ethel
  • Business Investment

SoftBank Ventures Asia Leads $5.8 Million Investment In Korean Autonomous Shipping Startup

2 days ago Ethel
  • Business Investment

Allu Arjun Pushpa Movie Hindi Dubbed: Revealed! Shreyas Talpade is the artist behind dubbing in blockbuster film

3 days ago Ethel

Recent Posts

  • How to find products to sell online
  • My Investment Portfolio Is Down 25%. Here’s Why I’m Not Worried | Smart Change: Personal Finance
  • Small Business Week Spotlight: 5 Exceptional Franchisees
  • Expect Loss Pressures to Continue in the P&C Industry Due to Inflation, Supply Chain and Riskier Driving Behavior, New Triple-I/Milliman Report Shows
  • ‘I chose to have an abortion’ years ago

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • December 2016

https://bayar.ooo/category/pajak/pajak-bumi-dan-bangunan

https://www.godsseo.my.id/category/konten/

Visit Now

Porsche Car

BL

LP

TL

Intellifluence Trusted Blogger

You may have missed

  • Business News

How to find products to sell online

2 hours ago Ethel
  • Business Investment

My Investment Portfolio Is Down 25%. Here’s Why I’m Not Worried | Smart Change: Personal Finance

3 hours ago Ethel
  • Bbc Business

Small Business Week Spotlight: 5 Exceptional Franchisees

4 hours ago Ethel
  • P&C Insurance

Expect Loss Pressures to Continue in the P&C Industry Due to Inflation, Supply Chain and Riskier Driving Behavior, New Triple-I/Milliman Report Shows

23 hours ago Ethel
  • General

‘I chose to have an abortion’ years ago

1 day ago Ethel
infociudad24.com Copyright © All rights reserved. | CoverNews by AF themes.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT